| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Outline of Final Research Achievements |
Isocitrate dehydrogenase 1/2 (IDH1/2) mutations have been reported in gliomas, and are remarkably specific to a single codon in the conserved and functionally important arginine 132 residue (R132) of IDH1 or arginine 172 residue (R172) of IDH2. To date, we have established several monoclonal antibodies (mAbs) specific for IDH1/2 mutations. Here, we established MsMab-1 mAb that reacts with IDH1-R132H, IDH1-R132S, IDH1-R132G, and IDH2-R172M, but not with wild type IDH1/2. MsMab-1 stained the IDH1-R132S or IDH1-R132G -expressing glioma cells in immunohistochemistry. MsMab-1 is expected to be useful for immunohistochemical determination of IDH1/2 mutation-bearing tumors.
|
